TAC (docetaxel, doxorubicin, and cyclophosphamide) adjuvant chemotherapy supported by G-CSF without dose-reduction in node-positive breast cancer

被引：0
|
作者：
Suh, Y. [1 ,2 ,3 ]
Oh, S. [1 ,2 ,3 ]
Song, B. [1 ,2 ,3 ]
Jung, S. [1 ,2 ,3 ]
机构：
[1] Cathol Univ Korea, St Vincent Hosp, Suwon, South Korea
[2] CUK, Inchon St Mary Hosp, Inchon, South Korea
[3] CUK, Seoul St Mary Hosp, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11606
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Weight gain after adjuvant TAC (docetaxel, doxorubicin, and cyclophosphamide) chemotherapy for node-positive breast cancer
    Suh, Y.
    Oh, S.
    Song, B.
    Jung, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Prophylactic pegfilgrastim support with adjuvant docetaxel, doxorubicin and cyclophosphamide (TAC) in node-positive breast cancer patients
    Rifa, Juli
    Del Alba, A. Gonzalez
    Perello, A.
    Alarcon, J.
    Avella, A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 112 - 112
  • [3] Weight change and its impact on prognosis after adjuvant TAC (docetaxel–doxorubicin–cyclophosphamide) chemotherapy in Korean women with node-positive breast cancer
    Ye Won Jeon
    Seung Taek Lim
    Hyun Joo Choi
    Young Jin Suh
    [J]. Medical Oncology, 2014, 31
  • [4] Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
    Mirzaei, Hamid Reza
    Rasekh, Parisa Sabet
    Nasrollahi, Fatemeh
    Rasekh, Parto Sabet
    Tirabad, Zahra Akbari
    RezaMoein, Hamid
    Pour, Taban Ghaffari
    Hajian, Parastoo
    [J]. INTERNATIONAL JOURNAL OF BREAST CANCER, 2013, 2013
  • [5] The optimal timing and duration of daily G-CSF for primary prophylaxis after adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy in breast cancer patients
    Kim, Z.
    Lee, J. E.
    Lee, J.
    Hur, S. M.
    Han, S. W.
    Kim, S. Y.
    Lim, C. W.
    [J]. BREAST, 2019, 44 : S18 - S18
  • [6] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Au, Heather-Jane
    Golmohammadi, Kamran
    Younis, Tallal
    Verma, Shailendra
    Chia, Stephen
    Fassbender, Konrad
    Jacobs, Philip
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 579 - 587
  • [7] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Heather-Jane Au
    Kamran Golmohammadi
    Tallal Younis
    Shailendra Verma
    Stephen Chia
    Konrad Fassbender
    Philip Jacobs
    [J]. Breast Cancer Research and Treatment, 2009, 114 : 579 - 587
  • [8] Weight change and its impact on prognosis after adjuvant TAC (docetaxel-doxorubicin-cyclophosphamide) chemotherapy in Korean women with node-positive breast cancer
    Jeon, Ye Won
    Lim, Seung Taek
    Choi, Hyun Joo
    Suh, Young Jin
    [J]. MEDICAL ONCOLOGY, 2014, 31 (03)
  • [9] Dose-dense (DD) two-weekly docetaxel/doxorubicin/cyclophosphamide (TAC) with G-CSF support compared to standard adjuvant TAC in breast cancer patients
    Latifzadeh, S. Z.
    Salimi, M.
    Naghnaeian, M.
    Entezari, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required
    Lakhanpal, Roopa
    Stuart-Harris, Robin
    Chan, Arlene
    Kotasek, Dusan
    Beith, Jane
    Cuff, Katharine
    Bastick, Patricia
    Lee, Clara
    [J]. BREAST CANCER MANAGEMENT, 2013, 2 (05) : 367 - 374
12345